Hyris Ltd founded in London
Seed round da 1M€, with 1.5M€ contributions.
R&D facilities open in Milan, Italy
First NanoHybrid patent, Trieste laboratory.
The HYRIS bCUBE™ 1.0 completes the first successful run.
First client orders are booked, third-party integration activities start.
Key customer demos and technical co-development.
First commercial revenues are booked.
Hyris obtains the Seal of Excellence of the European Commission.
Official birth. Start of Sagitta and NanoHybrid development. Patent on biosensors.
Hyris announces partnership and entry into the Botanicals application area.
HYRIS bCUBE™ 2.0 is available for sale.
First prototype. Raised 4M€ from 1,150 shareholders. Three new patents filed.
Obtained ISO 13485. Virological collaboration and two patents on biomarkers.
Hyris launches its product line for Probiotics strains identification.
Clinical validation of LadyMed. Distribution channel testing.
Hyris launches its test for the identification of the SARS-CoV-2 on environmental surfaces.
Hyris receives Series-A funding.
Entrance in the healthcare sector, with CE-IVD marking and Health Canada approval for SARS-CoV-2 human specimend test.
Partnership with Menarini for Coronamelt and Coronamelt Var (PCR Covid).
Hyris presents its new Brand Identity, supporting its fast growth worldwide.
HYRIS bCUBE 3™ is available for sale.
Hyris obtains ISO9001 and ISO13485 certifications.
Menarini starts production. Coronamelt Var coming in September.
Hyris obtains IS27001 certification.
First marketplace applications in product catalog.
Reverse takeover with Hyris. Integrated group for molecular diagnostics.
2024
Integration
Integration between Hyris and Ulisse Biomed is completed. The Group is ready to embrace the new industrial project.
New investors
Algebris becomes a strategic Ulisse Biomed shareholder with a capital increase worth €1,3mln.
2025
Second phase of Malaria Surveillance Project
Gates Foundation confirms funding for the second phase of the Malaria Surveillance project, in collaboration with the John's Hopkins University e CRID.